Atezolizumab, a fully humanized monoclonal anti PD-L1 antibody, is the first immune checkpoint inhibitor (ICI) to be approved in combination with carboplatin and etoposide for the treatment of ES-SCLC [14,15,16]. Here, CD274 is linked to small cell lung carcinoma.